Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Convertible Debt (2022 - 2025)

Historic Convertible Debt for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $198.3 million.

  • Gossamer Bio's Convertible Debt rose 49.27% to $198.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.3 million, marking a year-over-year increase of 49.27%. This contributed to the annual value of $197.5 million for FY2024, which is 47.41% up from last year.
  • Gossamer Bio's Convertible Debt amounted to $198.3 million in Q3 2025, which was up 49.27% from $198.0 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Convertible Debt high stood at $198.3 million for Q3 2025, and its period low was $195.1 million during Q1 2022.
  • For the 4-year period, Gossamer Bio's Convertible Debt averaged around $196.6 million, with its median value being $196.6 million (2023).
  • In the last 5 years, Gossamer Bio's Convertible Debt surged by 43.37% in 2023 and then surged by 49.27% in 2025.
  • Over the past 4 years, Gossamer Bio's Convertible Debt (Quarter) stood at $195.7 million in 2022, then increased by 0.45% to $196.6 million in 2023, then increased by 0.47% to $197.5 million in 2024, then grew by 0.37% to $198.3 million in 2025.
  • Its Convertible Debt stands at $198.3 million for Q3 2025, versus $198.0 million for Q2 2025 and $197.8 million for Q1 2025.